SCHEMBL639847

SCHEMBL639847

Cc1cccc(C)c1Cn1c(-c2ccccc2OCC(N)=O)nc2ccccc21

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.50
NPSR1 Q6W5P4 2/20 0.50
LMNA P02545 2/20 0.50
HTT P42858 2/20 0.50
PLA2G2A P14555 5/20 0.46
ALDH1A1 P00352 3/20 0.45
GAA P10253 2/20 0.45
RECQL P46063 1/20 0.45
KMT2A Q03164 3/20 0.42
MEN1 O00255 2/20 0.42
MAPT P10636 1/20 0.42
HPGD P15428 1/20 0.42
ALOX15 P16050 1/20 0.42
TSHR P16473 1/20 0.42
NPY1R P25929 1/20 0.42
MAPK1 P28482 1/20 0.42
NPY2R P49146 1/20 0.42
HSD17B10 Q99714 1/20 0.42
SMN1; SMN2 Q16637 4/20 0.41
PDPK1 O15530 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2906933 0.93 NPSR1 (0.53) KDM4ENPSR1LMNAHTTPLA2G2A
SCHEMBL2907639 0.90 PLA2G2A (0.44) KDM4ENPSR1LMNAHTTPLA2G2A
SCHEMBL2901560 0.90 NPSR1 (0.42) KDM4ENPSR1LMNAHTTPLA2G2A
SCHEMBL2908237 0.89 HTT (0.58) KDM4ENPSR1LMNAHTTPLA2G2A
SCHEMBL2910004 0.89 ALDH1A1 (0.45) KDM4ENPSR1LMNAHTTPLA2G2A
SCHEMBL2905631 0.89 LMNA (0.51) KDM4ENPSR1LMNAHTTPLA2G2A
SCHEMBL638972 0.89 BRD4 (0.41) KDM4ENPSR1LMNAHTTPLA2G2A
SCHEMBL2909757 0.88 KCNN4 (0.47) KDM4ENPSR1LMNAHTTPLA2G2A
SCHEMBL2902355 0.87 HTT (0.44) KDM4ENPSR1LMNAHTTPLA2G2A
SCHEMBL638729 0.87 PLA2G2A (0.43) KDM4ENPSR1LMNAHTTPLA2G2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2121627-B1 BENZIMIDAZOLE DERIVATIVES MERCK PATENT GMBH (DE) 2010-08-18 EP claimed
US-8119675-B2 Benzimidazole derivatives MERCK PATENT GMBH (DE) 2012-02-21 US disclosed
US-8119675-B2 Benzimidazole derivatives MERCK PATENT GMBH (DE) 2012-02-21 US disclosed
EP-2121627-B1 BENZIMIDAZOLE DERIVATIVES MERCK PATENT GMBH (DE) 2010-08-18 EP disclosed
EP-2121627-B1 BENZIMIDAZOLE DERIVATIVES MERCK PATENT GMBH (DE) 2010-08-18 EP disclosed
US-20100016372-A1 Benzimidazole Derivatives MERCK PATENT GMBH (DE) 2010-01-21 US disclosed
US-20100016372-A1 Benzimidazole Derivatives MERCK PATENT GMBH (DE) 2010-01-21 US disclosed
WO-2008101586-A1 BENZIMIDAZOLE DERIVATIVES MERCK PATENT GMBH (DE) 2008-08-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100016372-A1 Benzimidazole Derivatives GPR119, GLP1R, H1-3 KDM4E 1159/4885NPSR1 2609/4885LMNA 2955/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.